Home / Health / Olema Oncology Eyes Mid-2028 Launch Amidst Promising Data
Olema Oncology Eyes Mid-2028 Launch Amidst Promising Data
12 Nov
Summary
- Olema Oncology presented breast cancer pipeline updates and commercial plans at the Stifel Healthcare Conference.
- Palazestrant's Phase III readout is expected in early 2025, with a potential mid-2028 launch.
- The company ended Q3 with $414 million in cash, supporting operations into the planned palazestrant launch window.
Olema Oncology outlined significant progress for its breast cancer pipeline at the Stifel 2026 Healthcare Conference on November 11, 2026. The company shared its long-term commercial plans and detailed the promise of its drug candidates, palazestrant and OP-3136.
Key updates included the upcoming Phase III readout for OPERA-01, expected in the first quarter of 2025. This trial is crucial for confirming earlier signals and supporting a potential mid-2028 launch for palazestrant. Olema Oncology also announced new combination data expected in December.
Financially, Olema Oncology reported ending the third quarter with $414 million in cash. This strong cash position is projected to sustain operations through the anticipated palazestrant launch window, provided the crucial Phase III data prove positive.
The company is actively preparing for a U.S. launch and seeking an international collaborator. Multiple data presentations are scheduled for the San Antonio Breast Cancer Symposium, further detailing the progress of palazestrant and OP-3136.
Olema Oncology is also advancing its KAT6 inhibitor, OP-3136, and exploring its potential combination with palazestrant. The company anticipates presenting these advancements and future catalyst timelines, reinforcing its commitment to addressing significant unmet needs in breast cancer treatment.
